Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women

Cancer Research

Volumn 72, Issue 3, 2012, Pages 696-706

  Eliassen, A Heather ^a,b   Spiegelman, Donna ^b   Xu, Xia ^c   Keefer, Larry K ^e   Veenstra, Timothy D ^c   Barbieri, Robert L ^a   Willett, Walter C ^a,b   Hankinson, Susan E ^a,b,d   Ziegler, Regina G ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EPIMESTROL; ESTRADIOL; ESTROGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LUTEAL PHASE; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TANDEM MASS SPECTROMETRY; URINALYSIS; URINARY EXCRETION;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; CHROMATOGRAPHY, LIQUID; ESTRIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MOLECULAR STRUCTURE; MULTIVARIATE ANALYSIS; PREMENOPAUSE; RISK ASSESSMENT; RISK FACTORS; TANDEM MASS SPECTROMETRY;

EID: 84863011771     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2507     Document Type: Article

References (56)

1. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
2. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125:791-9. (Pubitemid 17066478)
3. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85. (Pubitemid 2077549)
4. Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 1994;140:518-25. (Pubitemid 24285934)
5. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 1997;75:1075-9. (Pubitemid 27122629)
6. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000;9:575-9. (Pubitemid 30396179)
7. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004;112:312-8. (Pubitemid 39244371)
8. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
9. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406-15. (Pubitemid 44530717)
10. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
11. Schutze N, Vollmer G, Knuppen R. Catecholestrogens are agonists of estrogen receptor dependent gene expression in MCF-7 cells. J Steroid Biochem Mol Biol 1994;48:453-61. (Pubitemid 24171870)
12. Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 2000;95-112.
13. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-86. (Pubitemid 37412587)
14. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A 1988;85:7831-5.
15. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006;1766:63-78.
16. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000;75-93.
17. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A 1985;82:6295-9. (Pubitemid 16222871)
18. Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-9. (Pubitemid 27295229)
19. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998;27:294-9. (Pubitemid 128518764)
20. Zheng W, Dunning L, Jin F, Holtzman J. Correspondence re: G. C. Kabat et al., Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol., Biomark. Prev., 6: 505-509, 1997. Cancer Epidemiol Biomarkers Prev 1998;7:85-6. (Pubitemid 28087147)
21. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, et al. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:1067-72. (Pubitemid 29293046)
22. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982;79:3047-51. (Pubitemid 12058614)
23. Adlercreutz H, Fotsis T, Hockerstedt K, Hamalainen E, Bannwart C, Bloigu S, et al. Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem 1989;34:527-30. (Pubitemid 20061839)
24. Fowke JH, Qi D, Bradlow HL, Shu XO, Gao YT, Cheng JR, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids 2003;68:65-72. (Pubitemid 35418304)
25. Kabat GC, O'Leary ES, Gammon MD, Sepkovic DW, Teitelbaum SL, Britton JA, et al. Estrogen metabolism and breast cancer. Epidemiology 2006;17:80-8.
26. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78:1250-5. (Pubitemid 28479160)
27. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635-40.
28. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005;14:2137-42. (Pubitemid 41603258)
29. Cauley JA, Zmuda JM, Danielson ME, Ljung BM, Bauer DC, Cummings SR, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003;14:740-4. (Pubitemid 40417025)
30. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2029-35.
31. Arslan AA, Shore RE, Afanasyeva Y, Koenig KL, Toniolo P, Zeleniuch-Jacquotte A. Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2009;18:2273-9.
32. Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, et al. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 2005;77:6646-54. (Pubitemid 41504449)
33. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983;25:165-72. (Pubitemid 13540616)
34. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-61. (Pubitemid 19116001)
35. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 1992;136:1400-13. (Pubitemid 23046425)
36. Eliassen AH, Ziegler RG, Rosner B, Veenstra TD, Roman JM, Xu X, et al. Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 2009;18:2860-8.
37. Willett WC. Nutritional epidemiology. 2nd ed. New York: Oxford University Press; 1998.
38. Barnea ER, MacLusky NJ, Naftolin F. Kinetics of catechol estrogen-estrogen receptor dissociation: a possible factor underlying differences in catechol estrogen biological activity. Steroids 1983;41:643-56. (Pubitemid 14242687)
39. Seeger H, Wallwiener D, Kraemer E, Mueck AO. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006;54:72-7.
40. Vandewalle B, Lefebvre J. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61:239-46. (Pubitemid 19038903)
41. Miyairi S, Ichikawa T, Nambara T. Structure of the adduct of 16 alpha-hydroxyestrone with a primary amine: evidence for the Heyns rearrangement of steroidal D-ring alpha-hydroxyimines. Steroids 1991;56:361-6.
42. Lustig RH, Mobbs CV, Pfaff DW, Fishman J. Temporal actions of 16 alpha-hydroxyestrone in the rat: comparisons of lordosis dynamics with other estrogen metabolites and between sexes. J Steroid Biochem 1989;33:417-21. (Pubitemid 19236143)
43. Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697-702. (Pubitemid 36592404)
44. Hurh YJ, Chen ZH, Na HK, Han SY, Surh YJ. 2-Hydroxyestradiol induces oxidative DNA damage and apoptosis in human mammary epithelial cells. J Toxicol Environ Health A 2004;67:1939-53. (Pubitemid 39488865)
45. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008;122:1949-57. (Pubitemid 351441183)
46. Gaikwad NW, Yang L, Pruthi S, Ingle JN, Sandhu N, Rogan EG, et al. Urine biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer (Auckl) 2009;3:1-8.
47. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992;84:634-8.
48. Liu ZJ, Zhu BT. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol 2004;88:265-75. (Pubitemid 38553758)
49. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 2006;147:4132-50. (Pubitemid 44274976)
50. Key TJ, Wang DY, Brown JB, Hermon C, Allen DS, Moore JW, et al. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer 1996;73:1615-9. (Pubitemid 26235394)
51. Taioli E, Im A, Xu X, Veenstra TD, Ahrendt G, Garte S. Comparison of estrogens and estrogen metabolites in human breast tissue and urine. Reprod Biol Endocrinol 2010;8:93.
52. Strauss JF, Barbieri RL. Yen and Jaffe's reproductive endocrinology. 5th ed. Philadelphia, PA: Elsevier Saunders; 2004.
53. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst 2008;100:218-21. (Pubitemid 351480544)
54. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28. (Pubitemid 38263181)
55. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-65. (Pubitemid 40081323)
56. Baird DD, McConnaughey DR, Weinberg CR, Musey PI, Collins DC, Kesner JS, et al. Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. Epidemiology 1995;6:547-50.